Onasemnogene Abeparvovec in Patients With SMA: Interim Results of the RESTORE Registry in Japan.
Kayoko Saito, Kamal Benguerba, Ken Tsuchida...
https://pubmed.ncbi.nlm.nih.gov/42265796/Actively Recruiting
Led by Novartis Pharmaceuticals · Updated on 2025-01-31
700
Participants Needed
99
Research Sites
N/A
Total Duration
Spinal muscular atrophy SMA is a genetic disorder caused by changes in the SMN1 gene, leading to low SMN protein levels and problems with motor neurons. It is an inherited disease that mainly affects children and is a leading cause of infant death due to genetic conditions. This research aims to observe patients with SMA over time to understand long-term outcomes with new treatments and to evaluate the long-term safety and effects of the investigational therapy OAV-101. This is a prospective, multinational, non-interventional observational study where patients receive their usual clinical care without changes directed by the study. Treatments such as Zolgensma may be given according to normal clinical practice, but this is not controlled by the study protocol. Patients will be followed for up to 15 years or until death, with no extra visits or tests beyond what is normally done for SMA care. Participants will be evaluated through regular clinical assessments based on their normal care schedule, with data collected at baseline and at intervals of every 6 months for the first 2 years, then yearly for up to 15 years. Researchers will measure survival rates, motor function scores like CHOP-INTEND and HFMSE, hospitalizations, quality of life, use of ventilator, nutritional, and mobility supports, as well as any treatment-related side effects during this long-term follow-up.
CONDITIONS
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
N
Novartis Gene Therapies
N
Novartis Gene Therapies
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Novartis Pharmaceuticals
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 15 years or until death, whichever is sooner
Participants who undergo routine care are observed for long-term outcomes and safety related to spinal muscular atrophy (SMA). Measurements are collected before and after routine healthcare.
Baseline visit, then every 6 months for 2 years, followed by annual visits up to 15 years
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Kayoko Saito, Kamal Benguerba, Ken Tsuchida...
https://pubmed.ncbi.nlm.nih.gov/42265796/Yasemin Erbaş, Laurent Servais, Perry B Shieh...
https://pubmed.ncbi.nlm.nih.gov/41217888/Elaine A Sugarman, Narasimhan Nagan, Hui Zhu...
https://pubmed.ncbi.nlm.nih.gov/21811307/Novartis Pharmaceuticals
Lead Sponsor